ONGOING CLINICAL TRIALS

While the Leeper laboratory predominantly focuses on fundamental vascular biology research, we maintain an active clinical research program with the belief that this bridge is critical for the acceleration of bench-to-bedside discoveries.   We are currently engaged in several early-phase clinical trials directed towards vascular regeneration, including the randomized, blinded and placebo-controlled NIH-funded PACE trial investigating the role of autologous stem cells for peripheral vascular disease patients.  We also direct the Genetic Determinants of Peripheral Artery Disease (GenePAD) study, which aims to determine the physiologic, genomic and metabolomic underpinnings of vascular disease.  Studies that are actively enrolling are listed here in the Research and Scholarship Section.  Please contact Fouzia Khan with any additional inquires.

  • PACE trial: “Bone Marrow Derived ALDH Bright Cells in Intermittent Claudication”.  Cardiovascular Cell Therapy Research Network (CCTRN), Phase II, Sponsor: NHLBI. Co-Investigator.
  • PPI and Cardiovascular Health Trial:  “Effect of Proton Pump Inhibitors on Endothelial Function”.  Phase I, Sponsor: Stanford (Investigator Initiated). Principle Investigator.
  • EUCLID Trial. “A randomised, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease (Examining Use of tiCagreLor In paD).  Phase III, Sponsor: Astra-Zeneca. Site Principle Investigator.
  • VOYAGER study: “An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures.”  Phase III, Sponsor: Bayer.  Site Principle Investigator.
  • mHealth in Vascular Disease: “Incentivizing Physical Activity Through Activity Monitoring Interventions in PAD”.  Phase I, Sponsor: Stanford (Investigator Initiated).  Co-Investigator.
  • Genetics of Peripheral Vascular Disease: “Study on the genetic underpinnings of peripheral vascular disease”.  GWAS meta-analysis.  Co-Investigator.